Lisa Miller
Vermögen: 3 Mio $ am 31.08.2026
Vermögen: 3 Mio $ am 31.08.2026
Lisa K.
Miller is currently Chief Operating Officer at Lifestance Health Group, Inc., a position starting in 2026.
Formerly, Ms. Miller was Chief Executive Officer at Invo Healthcare Holdings from 2021 to 2022 and Executive Vice President at Insight Capital Research & Management, Inc. from 1988 to 2008.
Education includes graduate studies at the University of Medicine & Dentistry of New Jersey, undergraduate studies at Oregon State University, and an MBA from Columbia Business School.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 10.08.2026 | 281’289 ( 0.07% ) | 3 Mio $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| LIFESTANCE HEALTH GROUP, INC. | Geschäftsführer | 10.03.2026 |
| Unternehmen | Position | Ende |
|---|---|---|
Invo Healthcare Holdings
Invo Healthcare Holdings Medical/Nursing ServicesHealth Services Provides special education and related services for children with developmental delays and disabilities | Geschäftsführer | 01.04.2022 |
Insight Capital Research & Management, Inc.
Insight Capital Research & Management, Inc. Investment ManagersFinance Insight Capital Research & Management (ICRM) is a growth manager that employs quantitative analysis, fundamental research and price performance analysis to identify attractive, rapidly-growing companies. The firm offers a variety of growth equity portfolios, including small-cap, small/mid-cap, large-cap and concentrated. ICRM uses a disciplined, 3-step process to evaluate the investable universe of actively traded US public companies. Their process includes proprietary quantitative analysis, fundamental analysis and stock price performance analysis. The firm begins with a quantitative screening that identifies and ranks companies based on their stock prices relative performance versus the market. To mitigate relative investment risk, ICRM also analyzes the return series risk profiles. Their quantitative analysis is conducted across several time periods and the universe of stocks is regressed against broad market indices. ICRM ranks the universe of stocks based on the ratio of alpha to standard deviation. This results in a list of stocks with the strongest history of outperforming the market while taking into account low historical variance relative to the benchmark index. ICRM's quantitative process also produces a relative strength score for each stock which further narrows the number of companies that are evaluated fundamentally. For each strategy, the firm reviews the top-ranked 500 companies identified through their quantitative research. Typically, 7 to 10 new companies warrant fundamental analysis. ICRM's fundamental analysis seeks to identify companies with strong, sustainable growth in sales and earnings. ICRM looks for companies with highly defensible competitive advantages, rapidly growing markets and exceptional management teams. They review financial statements to determine each company's ROE, debt leverage, margin improvement, cash generation, balance sheet strength and overall quality of earnings and assets. They pay particular attention to a company's market positioning, its reputation, the demand outlook for its products or services, the expected growth in its addressable market and competitive threats. Before a stock is selected for purchase, ICRM analyzes the relative strength of each stock to ensure that those stocks with favorable quantitative characteristics also have also delivered high absolute rates of return. They calculate relative strength by ranking all stocks in the universe by performance over several time periods, with greater weight placed on the most recent data covering the time period in question. Before a stock is purchased, ICRM also reviews it trading history. ICRM's Small-Cap Growth portfolio seeks to invest in the fastest growing small-cap companies. The strategy targets companies in the market-cap range of the Russell 2000 Growth Index. The portfolio typically holds an average of 37 positions. The firm's Institutional Small-Cap Growth portfolio seeks to invest in the fastest growing small-cap companies. The strategy targets companies in the market-cap range of the Russell 2000 Growth Index. The portfolio typically holds an average of 41 positions. ICRM's Concentrated Growth portfolio seeks to invest in a concentrated portfolio of the fastest growing companies. The strategy targets companies in the market-cap range of the Russell 3000 Growth Index. The portfolio typically holds an average of 14 positions. The firm's Large-Cap Growth portfolio seeks to invest in the fastest growing large-cap companies. The strategy targets companies in the market-cap range of the Russell 1000 Growth Index. The portfolio typically holds an average of 36 positions. Though not limited by sector, ICRM tends to invest in the stocks of companies in the electronic technology, consumer non-durables, health technology, consumer durables, retail, technology services and manufacturing sectors. The firm invests primarily in the stocks of US companies, but also has investments in Asia, Europe, Latin America and the Middle East. They invest across all market-caps. ICRM maintains a very high turnover rate. | Geschäftsführer | 31.03.2008 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 6 |
|---|---|
Insight Capital Research & Management, Inc.
Insight Capital Research & Management, Inc. Investment ManagersFinance Insight Capital Research & Management (ICRM) is a growth manager that employs quantitative analysis, fundamental research and price performance analysis to identify attractive, rapidly-growing companies. The firm offers a variety of growth equity portfolios, including small-cap, small/mid-cap, large-cap and concentrated. ICRM uses a disciplined, 3-step process to evaluate the investable universe of actively traded US public companies. Their process includes proprietary quantitative analysis, fundamental analysis and stock price performance analysis. The firm begins with a quantitative screening that identifies and ranks companies based on their stock prices relative performance versus the market. To mitigate relative investment risk, ICRM also analyzes the return series risk profiles. Their quantitative analysis is conducted across several time periods and the universe of stocks is regressed against broad market indices. ICRM ranks the universe of stocks based on the ratio of alpha to standard deviation. This results in a list of stocks with the strongest history of outperforming the market while taking into account low historical variance relative to the benchmark index. ICRM's quantitative process also produces a relative strength score for each stock which further narrows the number of companies that are evaluated fundamentally. For each strategy, the firm reviews the top-ranked 500 companies identified through their quantitative research. Typically, 7 to 10 new companies warrant fundamental analysis. ICRM's fundamental analysis seeks to identify companies with strong, sustainable growth in sales and earnings. ICRM looks for companies with highly defensible competitive advantages, rapidly growing markets and exceptional management teams. They review financial statements to determine each company's ROE, debt leverage, margin improvement, cash generation, balance sheet strength and overall quality of earnings and assets. They pay particular attention to a company's market positioning, its reputation, the demand outlook for its products or services, the expected growth in its addressable market and competitive threats. Before a stock is selected for purchase, ICRM analyzes the relative strength of each stock to ensure that those stocks with favorable quantitative characteristics also have also delivered high absolute rates of return. They calculate relative strength by ranking all stocks in the universe by performance over several time periods, with greater weight placed on the most recent data covering the time period in question. Before a stock is purchased, ICRM also reviews it trading history. ICRM's Small-Cap Growth portfolio seeks to invest in the fastest growing small-cap companies. The strategy targets companies in the market-cap range of the Russell 2000 Growth Index. The portfolio typically holds an average of 37 positions. The firm's Institutional Small-Cap Growth portfolio seeks to invest in the fastest growing small-cap companies. The strategy targets companies in the market-cap range of the Russell 2000 Growth Index. The portfolio typically holds an average of 41 positions. ICRM's Concentrated Growth portfolio seeks to invest in a concentrated portfolio of the fastest growing companies. The strategy targets companies in the market-cap range of the Russell 3000 Growth Index. The portfolio typically holds an average of 14 positions. The firm's Large-Cap Growth portfolio seeks to invest in the fastest growing large-cap companies. The strategy targets companies in the market-cap range of the Russell 1000 Growth Index. The portfolio typically holds an average of 36 positions. Though not limited by sector, ICRM tends to invest in the stocks of companies in the electronic technology, consumer non-durables, health technology, consumer durables, retail, technology services and manufacturing sectors. The firm invests primarily in the stocks of US companies, but also has investments in Asia, Europe, Latin America and the Middle East. They invest across all market-caps. ICRM maintains a very high turnover rate. | Finance |
University of Medicine & Dentistry of New Jersey
University of Medicine & Dentistry of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oregon State University
Oregon State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Columbia Business School
Columbia Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Invo Healthcare Holdings
Invo Healthcare Holdings Medical/Nursing ServicesHealth Services Provides special education and related services for children with developmental delays and disabilities | Health Services |
Lifestance Health Group, Inc.
Lifestance Health Group, Inc. Medical/Nursing ServicesHealth Services Operates as a holding company with interests in providing outpatient mental health, spanning psychiatric evaluations & treatment, psychological and neuropsychological testing services | Health Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen